Recently, Professor Huang Xi, a high-level talent of the Organization Department of the CPC Central Committee, professor at Sun Yat-sen University, academic director of the Fifth Affiliated Hospital of Sun Yat-sen University, and chairman of Qinyuan Regenerative Medicine, led a delegation of ten to Shenzhen Cell Valley for collaborative discussions. Professor Shi Yuan Yuan, chairman and general manager of Shenzhen Cell Valley, warmly received the delegation with his team. The two sides engaged in in-depth and productive discussions on topics such as CDMO services for cell products and clinical research applications for innovative drugs.

    During the meeting, Chairman Shi Yuan Yuan first extended a warm welcome to Professor Huang Xi and his delegation. He provided a detailed introduction to Shenzhen Cell Valley's full industrial chain layout in the field of cell therapy, its core technology platforms, and the advantages of its one-stop CDMO services. Shi Yuan Yuan emphasized that Shenzhen Cell Valley boasts a robust quality system, advanced process development, and large-scale production capabilities, aiming to become a trusted partner for biopharmaceutical companies.

Professor Huang Xi expressed high recognition for Shenzhen Cell Valley's professional capabilities and technical platforms. He noted that Qinyuan Regenerative Medicine, leveraging the strong scientific research and clinical resources of Sun Yat-sen University and its Fifth Affiliated Hospital, has achieved a series of cutting-edge research results in regenerative medicine. The innovative drug project they intend to outsource for development holds significant clinical potential, and he looks forward to a powerful collaboration with an industry leader like Shenzhen Cell Valley. By leveraging its professional CDMO platform, they aim to efficiently advance the clinical translation and regulatory submission of the project.

The two sides conducted comprehensive and detailed discussions on specific cooperation details, including process development, quality research, GMP production, and regulatory documentation preparation, further clarifying the collaboration pathway and implementation standards. Both parties also expressed their commitment to accelerating the finalization of cooperation details, establishing a dedicated joint working group, and transitioning the project from negotiation to substantive implementation. This exchange yielded significant results, not only clearing obstacles for short-term collaboration but also laying a solid foundation for a long-term, stable strategic partnership. In the future, the two sides will fully leverage their respective strengths in cutting-edge scientific research, clinical resource integration, and industrial implementation, synergizing efforts across "research-translation-production" to accelerate the development and commercialization of innovative cell therapies. This will bring new treatment hope to patients and jointly inject fresh momentum into the high-quality development of China's biopharmaceutical industry.